

1 **Perceptions and priorities for the development of multiplex rapid diagnostic tests for**
2 **acute non-malarial fever in rural South and Southeast Asia:**
3 **an international modified e-Delphi survey**

5 **Short title:** Prioritization of analytes for acute non-malarial fever multiplex rapid diagnostic tests

7 **Authors:** Rusheng Chew^{1,2,3}; Salisa Lohavittayavikant¹; Matthew Mayer⁴; Nicholas PJ Day^{1,2}; Yoel
8 Lubell^{1,2}

10 **Affiliations:** ¹Mahidol Oxford Tropical Medicine Research Unit, Bangkok, Thailand; ²Centre for
11 Tropical Medicine and Global Health, University of Oxford, Oxford, UK; ³Faculty of Medicine,
12 University of Queensland, Brisbane, Australia; ⁴Freelance information technology consultant

14 **Corresponding author details:** Dr Rusheng Chew, Mahidol Oxford Tropical Medicine Research Unit,
15 3rd floor 60th Anniversary Chalermprakiat Building, 420/6 Ratchawithi Road, Ratchathewi, Bangkok
16 10400, Thailand. Email: chris@tropmedres.ac Phone: +66 2 203 6333

18 **Author contributions:** RC – conceptualization, methodology, investigation, formal analysis,
19 visualization, writing – original draft; SL – software, data curation, writing – review and editing; MM
20 – software, writing – review and editing; NPJD – supervision, funding acquisition, writing – review
21 and editing; YL – conceptualization, methodology, supervision, funding acquisition, writing – review
22 and editing

24 **Key words:** Fever; Delphi survey; rapid diagnostic test; Southeast Asia; South Asia

26 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Word count: 3078

27 **ABSTRACT**

28

29 **Background.** Fever is a common presenting symptom in low- and middle-income countries (LMICs).
30 It was previously assumed that malaria was the cause in such patients, but its incidence has declined
31 rapidly. The urgent need to develop point-of-care tests for the most important causes of non-
32 malarial acute febrile illness is hampered by the lack of robust epidemiological data. We sought to
33 obtain expert consensus on analytes which should be prioritized for inclusion in fingerprick blood-
34 based multiplex lateral flow rapid diagnostic tests (LF-RDTs) targeted towards four categories of
35 patients with acute non-malarial fever in South and Southeast Asian LMICs, stratified by age
36 (paediatric vs. adult) and care setting (primary vs. secondary care).

37 **Methodology/Principal Findings.** We conducted a two-round modified e-Delphi survey. A total of 84
38 panellists were invited, consisting of seven each from 12 countries, divided into three regional
39 panels (Mainland Southeast Asia, Maritime Southeast Asia, and South Asia). Panellists were asked to
40 rank their top seven analytes for inclusion in LF-RDTs to be used in each patient category, justify
41 their choices, and indicate whether such LF-RDTs should be incorporated into algorithm-based
42 clinical decision support tools. Thirty-six panellists (43%) participated in the first round and 44 (52%)
43 in the second. There was consensus that such LF-RDTs should be incorporated into clinical decision
44 support tools. At a minimum, these LF-RDTs should be able to diagnose dengue and enteric fever in
45 all patient categories. There was a clear preference to develop LF-RDTs for pathogens not readily
46 detected by existing technologies, and for direct diagnosis through antigen detection. Pathogen
47 biomarkers were prioritized over host inflammatory biomarkers, with CRP being the only one ranked
48 consistently highly.

49 **Conclusions/Significance.** Our results provide guidance on prioritizing analytes for inclusion in
50 context-specific multiplex LF-RDTs and similar platforms for non-malarial acute febrile illness, for
51 which there is an urgent unmet need.

52 **AUTHOR SUMMARY**

53

54 In rural South and Southeast Asia, most acute febrile illness was previously attributable to malaria
55 but the incidence of malaria is declining. To aid diagnosis and prognosis in patients presenting with
56 the common symptom of acute fever with no localising features but in whom malaria has been
57 excluded, there is an urgent need to develop minimally-invasive rapid diagnostic tests (RDTs) which
58 can test for multiple pathogen and host biomarkers. Obtaining expert consensus opinions on what
59 biomarkers these tests should detect will contribute greatly to their development, but there is a
60 paucity of robust epidemiological data on the diverse non-malarial causes of acute fever. We
61 determined the biomarkers which should be included in region-specific fingerprick blood-based RDTs
62 tailored to four patient categories differentiated by age and level of care, in the form of seven-item
63 lists ranked in decreasing order of priority. To provide context for these rank lists, we ascertained
64 the principal factors influencing expert priority-setting and explored perceptions of the clinical utility
65 of such RDTs. Our results provide essential region-specific guidance to aid development of RDTs for
66 acute non-malarial fever, for which there was strong consensus for their inclusion in clinical decision-
67 making tools for low- and semi-skilled healthcare staff.

68 **INTRODUCTION**

69

70 Fever is a common but non-specific sign of sepsis.[1] In regions with high burdens of infectious
71 diseases such as South and Southeast Asia, many patients present acutely with fever but without
72 localising signs and symptoms. It was previously assumed that malaria was the cause in most
73 patients presenting with such fevers, but the roll-out of highly accurate malaria rapid diagnostic tests
74 along with the success of public health efforts to eradicate malaria has resulted in a large decline in
75 malaria incidence.[2, 3] Febrile illnesses, however, are still a common cause for seeking medical care
76 in rural communities and, while early intervention is crucial in the management of sepsis, obtaining
77 clinical and/or microbiological diagnoses is difficult in these resource-poor settings.

78

79 Fingerprint blood-based rapid diagnostic tests for several other infectious diseases based on lateral
80 flow technology e.g., HIV and Ebola virus disease, have been developed and rolled out in both high-
81 and low-resource settings.[4, 5] These are generally immunoassays based on the detection of
82 microbial antigens and/or antibodies against the causative pathogens, although nucleic acid-based
83 assays have more recently been developed.[6] Similar to these pathogen biomarker assays, tests for
84 several host inflammatory biomarkers of potential diagnostic and/or prognostic significance are also
85 available.[7] The test kits comprise of a recognition layer containing the detection sites, combined
86 with a porous membrane which draws the fluid to be tested past the detection sites by capillary
87 action.[8] They are low-cost, simple to operate, require no specialised equipment, and can be used
88 at the point of care, returning results in 30 minutes or less, thus making them ideal for use in low-
89 resource settings.[9, 10]

90

91 These features, along with the endemicity of myriad infectious diseases in the region, poorly trained
92 health workforce, and lack of diagnostic microbiology capability create a pressing need for multiplex
93 lateral flow rapid diagnostic test kits (LF-RDTs) for multiple infections to guide patient management

94 with the minimum amount of test substrate. The use of multiple single-disease LF-RDTs is unlikely to
95 be cost-effective or logistically feasible, and is sub-optimal for patient comfort. However,
96 ascertainment of the most important infective aetiologies of fever to aid the development of
97 relevant multiplex LF-RDTs and other diagnostic tools in South and Southeast Asia is hampered by
98 the paucity of reliable epidemiological data covering not just incidence, but also disease burden in
99 terms of morbidity and mortality.[11] There is, thus, a high degree of uncertainty in prioritization of
100 pathogens for inclusion in such tests; furthermore, what little published evidence there is comes
101 mainly from cities, rather than rural areas where most of the population live.[12] In addition, there is
102 growing interest in augmenting pathogen-based diagnostics by assaying host biomarkers of
103 inflammation in parallel, in particular those which can assist in the differentiation viral from non-viral
104 infections, thus improving antimicrobial stewardship,[13] or predict or indicate severe disease, thus
105 improving the identification of patients who require escalation of care.[14]

106

107 Given the poor understanding of the epidemiology of febrile illness in South and Southeast Asia, we
108 conducted a modified e-Delphi survey to obtain expert consensus on pathogen-specific and host
109 inflammatory biomarker analytes which should be prioritized for inclusion in multiplex LF-RDTs with
110 fingerprick blood as the test substrate, for use in acutely febrile rural residents of South and
111 Southeast Asian low- and middle-income countries (LMICs) who test negative for malaria and in
112 whom the source of infection is unclear. We also aimed to explore the reasoning and contextual
113 background underlying the selection of these analytes.

114 **METHODS**

115

116 The survey was conducted over two rounds from 20 April to 20 June 2022, and delivered via
117 anonymous web-based questionnaires administered through a bespoke platform. Reminder emails
118 were sent weekly to optimize participation rates. Prior to launch, two experts who would have
119 otherwise been invited as panellists were asked to review the survey to ensure face validity,
120 readability, and usability.

121

122 Given the likely spatio-temporal heterogeneity in disease profiles, three regional panels were
123 assembled: South Asia (India, Bangladesh, Pakistan, and Nepal), Mainland Southeast Asia (Thailand,
124 Laos, Myanmar, Peninsular Malaysia, and Cambodia), and Maritime Southeast Asia (Indonesia,
125 Timor-Leste, and the Philippines). Countries were selected to ensure adequate geographical
126 representation, with at least one small country (in terms of relative population size) included per
127 panel.

128

129 ***Participant selection***

130

131 A total of 84 experts (seven from each country) were invited to participate in each round. Potential
132 panelists were shortlisted through searches of national infectious diseases and/or tropical medicine
133 specialty society office-bearers; leaders of health-related non-governmental organizations and
134 governmental bodies; researchers from university departments or faculties; and recommendations
135 of experts already selected. The final list was constructed based on work experience, expertise and
136 reputation, involvement in health policymaking, and publication record. To balance perspectives, at
137 least 30% of each regional panel were in non-clinical roles and at least 25% were women.
138 Participants had three weeks to complete each round of the survey, and were able to save and
139 return to their responses if they were unable to complete each round in one sitting.

140

141 ***First round***

142

143 In the first round, participants were provided with four scenarios in which they were required to
144 rank seven analytes from a list of pathogen-specific and host inflammatory biomarkers for
145 hypothetical LF-RDTs for acute (≤ 14 days duration) non-malarial fever of unclear source to be
146 developed for year-round use in each region. The four scenarios corresponded to four patient
147 categories stratified by age and level of care i.e., children (age > 28 days and < 15 years) and adults
148 (age ≥ 15 years) seeking healthcare in the community from village health workers or primary health
149 facilities, and being admitted to rural hospitals with limited diagnostic capacity, respectively.
150 Neonates were not included because neonatal febrile illness generally requires assessment and
151 thorough investigation in secondary or higher-level care.[15]

152

153 Pathogen biomarker options were based on a recent systematic review of published aetiological
154 studies and case reports on non-malarial fever in South and Southeast Asia,[16] while host
155 inflammatory biomarker options were selected on the basis of biological plausibility and a non-
156 systematic survey of the literature.[17, 18] Participants were able to recommend non-listed analytes
157 as well as refine the provided choices, such as specifying a particular type of antigen, and were asked
158 to explain the reasoning behind their decisions for each scenario. If a host inflammatory biomarker
159 was selected, participants were required to state its perceived utility from the following options:
160 'differentiation of viral and non-viral fever', 'as a marker of severity', 'both of these reasons', or
161 'other'.

162

163 To assess the perceived value of LF-RDTs in these patient categories, participants were asked
164 whether they would find such a test with a minimum sensitivity of 75% and minimum specificity of
165 90% across all targets helpful to guide clinical decision-making, and whether they would recommend

166 its inclusion in electronic algorithm-based clinical decision support tools for use in their countries.
167 Finally, to provide further context, participants were asked to rank what they perceived to be the
168 five commonest causes of acute febrile illness in their regions in terms of annual incidence.
169 Consensus was achieved if $\geq 80\%$ of the participants for each region agreed on a particular response.
170 Questions for which consensus was achieved in the first round were not repeated.

171

172 At the conclusion of the first round, participants were invited to provide free-text feedback on the
173 survey structure and questions. Free-text suggestions for improvement were analysed thematically
174 and used to inform the subsequent iteration of the questionnaire. Changes were made based on the
175 number of times an issue was raised, the practicality of the suggested change, and its relevance to
176 the context of the survey.

177

178 ***Second round***

179

180 All panellists were re-invited to participate in the second round run two weeks after the end of the
181 first, unless they explicitly declined to participate in the first round. The latter (n=10) were replaced
182 in the second round, while maintaining the gender and clinician balance described previously.

183

184 In this round, only options that had been selected in the first round for each scenario were included.
185 First-round respondents who participated in the second round were shown their previous answers
186 to each question. To assist participants in reaching consensus, the frequencies of every analyte
187 selected in each rank position, along with their sum of weighted scores, were shown graphically. An
188 analyte ranked first was assigned a weighted score seven times more than if it was ranked last.
189 Similarly, for the question on the commonest causes of acute febrile illness, an aetiology ranked first
190 was assigned a weighted score five times more than if it was ranked last. The factors influencing

191 participant reasoning for their rankings from the first round were analysed thematically and
192 presented as discrete options in this round.

193

194 In the event that consensus for each rank position was unable to be reached by the end of the
195 second round, agreement was quantified by constructing rank lists of the seven highest-scoring
196 analytes for each scenario and of the five highest-scoring aetiologies of febrile illness were
197 constructed.

198

199 Statistical analyses were performed using Microsoft Excel (Microsoft, Washington, USA).

200 **RESULTS**

201

202 Thirty-six experts participated in the first round and 44 in the second round, giving overall response
203 rates of 43% and 52%, respectively. Thirty-four of the 36 (94%) first round-respondents also
204 participated in the second round; in this round, regional panel response rates were between 38%
205 and 66%. Participant demographic and professional background details by region for both rounds
206 are shown in Table 1.

207

208 ***First round***

209

210 In all panels, there was consensus that such LF-RDTs would help clinical decision-making in all target
211 patient populations, and for the incorporation of these tests into electronic algorithm-based clinical
212 decision support tools for use in their respective countries.

213

214 The reasons given by participants for the ordering of their rank lists were distilled into the following
215 statements, which were used as response options in the second round: 'disease prevalence and/or
216 incidence in this age group and care setting', 'potential disease severity and need (or otherwise) for
217 antimicrobial therapy or referral', 'host biomarkers are more useful than aetiological diagnosis in this
218 age group and care setting', 'aetiological diagnosis is more useful than host biomarkers in this age
219 group and care setting', 'pathogens for which there are available RDTs should be prioritised',
220 'pathogens for which there are no available RDTs should be prioritised', and 'other'.

221

222 ***Second round***

223

224 The consensus threshold was not reached for any position in any rank list. Therefore, for each region
225 the seven highest-scoring analytes for each scenario and the five highest-scoring aetiologies of acute
226 febrile illness, based on the sums of their weighted scores, were used to construct the rank lists.

227

228 Across all regions, in both primary and secondary care settings and for both paediatric and adult
229 patients dengue NS1 and typhoidal *Salmonella* antigens occupied the top two rank positions (Figures
230 1–3). This is in keeping with the perception that dengue and enteric fevers are among the top five
231 causes of acute febrile illness in all regions (Figure 4), and with the unsurprising finding that
232 perceived disease incidence and/or prevalence was a primary factor in analyte selection (Figure 5).

233 Also in line with current evidence on the near-elimination of malaria, the disease was thought to be
234 a leading cause of acute febrile illness only in Maritime Southeast Asia (Figure 4).

235

236 In mainland Southeast Asia, *Burkholderia pseudomallei*, *Orientia tsutsugamushi*, and *Rickettsia*
237 antigens also featured in the rank lists for each scenario, as did *Leptospira* antigen in maritime
238 Southeast Asia (Figures 1–3). While only *Rickettsia* was listed among the top five aetiologies of acute
239 febrile illness in mainland Southeast Asia (Figure 4), the inclusion of these organisms is reflective of
240 another major factor influencing analyte selection i.e., the prioritisation of pathogens which require
241 specific directed antimicrobial therapy and have the potential to cause severe disease (Figure 5).

242

243 There was a clear preference for antigen-based pathogen biomarkers over serological analytes,
244 including for pathogens like typhoidal *Salmonella* where such capillary blood-based rapid tests are
245 not yet available (Figures 1–3). This finding also reflects the view of the majority of respondents that
246 pathogens for which there are no readily available RDTs should be prioritised for inclusion when
247 developing multiplex LF-RDTs (Figure 5).

248

249 The only host inflammatory biomarker which featured prominently in this survey was C-reactive
250 protein (CRP). CRP was included in all rank lists except those for adult secondary care in Mainland
251 and Maritime Southeast Asia (Figures 1–3). However, it was most frequently found in the bottom
252 half of rank lists, indicative of the majority opinion that host biomarkers are less useful than
253 microbiological diagnosis (Figure 5).

254
255 Furthermore, while twenty-eight (64%) respondents across all panels ranked CRP in one or more
256 scenarios, there was little agreement on use case. Eight (29%) believed it was a good discriminator
257 between viral and non-viral infections in all scenarios in which CRP featured in their rank lists, while
258 two (7%) believed it to be a good marker of disease severity. A further eight (29%) thought CRP was
259 able to fulfil both use cases, while 10 (36%) were of the opinion that use case varies depending on
260 patient age and care setting.

261
262 For the scenario-based questions, the top-ranked three analytes in each rank list were unchanged
263 between the first and second rounds although their individual positions varied slightly, except for
264 the Maritime Southeast Asia and South Asia adult secondary care rank lists where the top-ranked
265 two analytes were constant between rounds. The top-ranked analyte in all rank lists in the first
266 round was either dengue NS1 antigen or typhoidal *Salmonella* antigen, demonstrating a degree of
267 convergence at the end of the survey as both these analytes occupied the top two positions in all
268 lists in the second round. The top three perceived aetiologies of acute febrile illness in all regions
269 were also unchanged between rounds.

Region	Characteristic		Round 1 (n, %)	Round 2 (n, %)		
Mainland Southeast Asia [n = 19 (54%) and 23 (66%) in rounds 1 and 2, respectively]	Country		Thailand	2 (11)	5 (22)	
			Laos	5 (26)	5 (22)	
			Cambodia	3 (16)	3 (13)	
			Myanmar	4 (21)	4 (17)	
			Peninsular Malaysia	5 (26)	6 (26)	
	Gender		Male	15 (79)	17 (74)	
			Female	4 (21)	6 (26)	
	Professional role	Clinical		Clinical infectious diseases	10 (52)	10 (43)
				Clinical infectious diseases and medical microbiology	4 (21)	5 (22)
				Other	1 (5)	2 (9)
		Non-clinical		Medical microbiology	3 (16)	3 (13)
				Epidemiology	2 (11)	1 (4)
				Microbiology	1 (5)	2 (9)
	Years of experience		0 to 5	0 (0)	1 (4)	
			>5 to 10	1 (5)	1 (4)	
>10 to 15			4 (21)	5 (22)		
>15 to 20			3 (16)	3 (13)		
>20			11 (58)	13 (57)		
Maritime Southeast Asia [n = 6 (29%) and 8 (38%) in rounds 1 and 2, respectively]	Country		Indonesia	2 (33)	3 (38)	
			Philippines	1 (17)	1 (13)	
			Timor-Leste	3 (50)	4 (50)	
	Gender		Male	1 (17)	3 (38)	
			Female	5 (83)	5 (62)	
	Professional role	Clinical		Clinical infectious diseases	5 (83)	5 (63)
				Clinical infectious diseases and medical microbiology	0 (0)	1 (13)
				Other	1 (17)	2 (25)
	Years of experience		>5 to 10	2 (33)	3 (38)	
>10 to 15			3 (50)	2 (25)		
>20			1 (17)	3 (38)		
South Asia [n = 11 (39%) and 13 (46%) in rounds 1 and 2, respectively]	Country		India	2 (18)	2 (15)	
			Nepal	3 (27)	4 (31)	
			Pakistan	4 (36)	5 (38)	
			Bangladesh	2 (18)	2 (15)	
	Gender		Male	7 (64)	7 (54)	
			Female	4 (36)	6 (46)	
	Professional role	Clinical		Clinical infectious diseases	7 (64)	7 (54)
				Clinical infectious diseases and medical microbiology	1 (9)	1 (8)
				Other	1 (9)	1 (8)
		Non-clinical		Medical microbiology	1 (9)	2 (15)
				Public health	0 (0)	1 (8)
				Other	1 (9)	1 (8)
	Years of experience		>10 to 15	0 (0)	3 (23)	
>15 to 20			4 (36)	3 (23)		
>20			7 (64)	7 (54)		

270

271

Table 1. Regional panel participant demographic and professional background details.

272 **DISCUSSION**

273

274 The results of this survey indicate that multiplex LF-RDTs for non-malarial acute febrile illness to be
275 developed for use in South and Southeast Asia should be able to diagnose dengue and enteric fever
276 in all age groups and care settings. There was also a clear desire for the development of LF-RDTs for
277 pathogens not readily detected by existing technologies, and for these new tests to diagnose
278 diseases directly through antigen detection. Pathogen biomarkers were prioritized over host
279 biomarkers, for which the only contender for inclusion was CRP although there was little agreement
280 on use case. The majority of the other pathogen biomarkers selected reflect the almost equal
281 consideration given to clinical and epidemiological burdens of disease. Importantly, there was strong
282 and early consensus that such LF-RDTs would aid clinical decision-making and that they should be
283 incorporated into algorithm-based clinical decision support tools.

284

285 Our study has several strengths. Firstly, the modified Delphi method is well-suited to address the
286 research question, given the challenges in collecting comprehensive epidemiological data before
287 commencing work on LF-RDT development. The Delphi survey is a well-established technique
288 facilitating consensus decision-making and avoiding domination by individual experts, as it is
289 anonymous, systematic, iterative, and inclusive of a range of opinions.[19, 20] Secondly, we adhered
290 to best practice by pre-specifying the consensus definition, panellist selection criteria, and closing
291 criterion, and by providing timely, well-structured controlled feedback.[21, 22] In addition, we
292 ensured generalizability through assembling appropriately-sized panels of suitably qualified
293 members from diverse backgrounds and countries,[21] and by taking steps to ensure that the
294 response rate for each panel exceeded the approximately 30% response rate typical of online
295 surveys.[23] Thirdly, the participant retention rate between the two rounds was high. However, by
296 re-inviting panellists who did not participate in the first round, we avoided the possibility of false
297 consensus and ensured optimal representation of perspectives.[24] Fourthly, although response

298 stability was not a closing criterion, the consistency of the top-ranked two to three responses to
299 each question between rounds is indicative of the reliability of our results.[22, 25]

300

301 The principal weakness of our study is that consensus, as per the prespecified definition, was not
302 reached with regard to analyte rankings. However, we had anticipated this possibility and, thus,
303 prespecified an alternative method of analyte prioritisation based on sums of weighted scores.

304 Secondly, for pragmatic reasons we only surveyed experts from 12 out of the 15 LMICs in South and
305 Southeast Asia. However, because panellist selection was weighted towards large countries both in
306 terms of area and population, our results are still likely to be of considerable benefit in informing the
307 development of LF-RDTs to be used in these regions.

308

309 Our results complement and extend previous work by Osborn et al. which, to our knowledge, is the
310 only other study which has attempted to address this important question. They conducted a global
311 prioritization exercise for a cartridge-based diagnostic test for pathogens causing severe febrile
312 illness without a known source in patients presenting to secondary care.[26] Unlike their study, ours
313 concentrated on acute non-malarial fever in both primary and secondary care settings with patients
314 stratified by age, included host inflammatory biomarkers as options, and adopted a more granular
315 regional focus. Both studies had typhoidal *Salmonella* as a top priority pathogen in addition to
316 leptospirosis and rickettsioses, but we also recognized dengue and melioidosis as other major
317 priorities given our emphasis on rural South and Southeast Asia. Additionally, for each pathogen we
318 explored what participants deemed the ideal analyte, as well as the motivations and reasoning
319 behind their choices. Our findings, therefore, add further layers of context which are essential to
320 ensuring acceptability and applicability, two key challenges facing the development and
321 implementation of any such LF-POCTs developed for use in these regions.[27]

322

323 The obvious implication of this study is its value in informing analyte selection for multiplex LF-RDT
324 development. In general, while current LF-RDT technologies do not yet permit the detection of more
325 than 2-3 analytes from fingerprick blood, new diagnostic methods which allow detection of more
326 analytes without an increase in sample volume are in development. Examples of these are CRISPR-,
327 aptamer-, and SOMAmer-based multiplex assays which will also facilitate adaptation of the analyte
328 panels, making them more context-specific.[28, 29] The seven-item rank lists constructed will, thus,
329 serve as a reference point as to which analytes to prioritise for inclusion in expanded panels in line
330 with the target product profile for multiplex multi-analyte diagnostic platforms for acute febrile
331 illness published by the World Health Organization.[30] Finally, we have also identified two key
332 questions for future research. The first is the validation of setting-specific CRP use cases and the
333 determination of cut-off levels to ensure sufficient sensitivity and specificity for each use case. The
334 second is the development and validation of antigen-based LF-RDTs for typhoidal *Salmonella*, since
335 no such tests have been developed despite the interest demonstrated by our study.

336

337 **ACKNOWLEDGEMENTS**

338

339 We thank the experts who participated in this study, a list of whom can be found in Supplemental
340 Appendix 1.

341

342 **COMPETING INTERESTS**

343

344 The authors declare no competing interests.

345

346 **ETHICAL APPROVAL**

347

348 Ethical approval was not necessary for this study.

349

350 **FUNDING**

351

352 This research was funded in whole, or in part, by the Wellcome Trust [215604/Z/19/Z]. RC was also

353 funded by the UK Government through a Commonwealth Scholarship, and the Royal Australasian

354 College of Physicians through the Bushell Travelling Fellowship in Medicine or the Allied Sciences.

355 The funders had no role in study design, data collection, data analysis, data interpretation or writing

356 of the manuscript. All authors had full access to the data and had final responsibility for the decision

357 to submit the manuscript for publication.

358

359 **DATA AVAILABILITY**

360

361 Data are available upon reasonable request. All data relevant to the study are included in the article

362 or uploaded as supplementary information.

363 **REFERENCES**

364

365 1. Rampersad A, Mukundan D. Fever. *Curr Opin Pediatr*. 2009;21(1):139-44. doi:

366 10.1097/MOP.0b013e32832130d2.

367 2. Mukkala AN, Kwan J, Lau R, Harris D, Kain D, Boggild AK. An Update on Malaria Rapid

368 Diagnostic Tests. *Curr Infect Dis Rep*. 2018;20(12):49. doi: 10.1007/s11908-018-0655-4.

369 3. Oyegoke OO, Maharaj L, Akoniyan OP, Kwoji I, Roux AT, Adewumi TS, et al. Malaria

370 diagnostic methods with the elimination goal in view. *Parasitol Res*. 2022;23(1):1-19. doi:

371 10.1007/s00436-022-07512-9.

372 4. Wongkanya R, Pankam T, Wolf S, Pattanachaiwit S, Jantarapakde J, Pengnongyang S, et al.

373 HIV rapid diagnostic testing by lay providers in a key population-led health service programme in

374 Thailand. *J Virus Erad*. 2018;4(1):12-5.

375 5. Wonderly B, Jones S, Gatton ML, Barber J, Killip M, Hudson C, et al. Comparative

376 performance of four rapid Ebola antigen-detection lateral flow immunoassays during the 2014-2016

377 Ebola epidemic in West Africa. *PLoS One*. 2019;14(3):e0212113. doi: 10.1371/journal.pone.0212113.

378 6. Liu T, Choi G, Tang Z, Kshirsagar A, Politza AJ, Guan W. Fingerpick Blood-Based Nucleic Acid

379 Testing on A USB Interfaced Device towards HIV self-testing. *Biosens Bioelectron*. 2022;209:114255.

380 doi: 10.1016/j.bios.2022.114255.

381 7. Teggert A, Datta H, Ali Z. Biomarkers for Point-of-Care Diagnosis of Sepsis. *Micromachines*

382 (Basel). 2020;11(3):286. doi: doi: 10.3390/mi11030286.

383 8. Anfossi L, Di Nardo F, Cavalera S, Giovannoli C, Baggiani C. Multiplex Lateral Flow

384 Immunoassay: An Overview of Strategies towards High-throughput Point-of-Need Testing.

385 *Biosensors (Basel)*. 2018;9(1):2. doi: 10.3390/bios9010002.

386 9. Posthuma-Trumpie GA, Korf J, van Amerongen A. Lateral flow (immuno)assay: its strengths,

387 weaknesses, opportunities and threats. A literature survey. *Anal Bioanal Chem*. 2009;393(2):569-82.

388 doi: 10.1007/s00216-008-2287-2.

- 389 10. Chappuis F, Alirol E, d'Acremont V, Bottieau E, Yansouni CP. Rapid diagnostic tests for non-
390 malarial febrile illness in the tropics. *Clin Microbiol Infect.* 2013;19(5):422-31. doi: 10.1111/1469-
391 0691.12154.
- 392 11. Newton PN, Guerin PJ. Febrile illness mapping-much of the world without data and without
393 evidence-based treatments. *BMC Med.* 2018;18(1):287. doi: 10.1186/s12916-020-01747-y.
- 394 12. Chandna A, Chew R, Shwe Nwe Htun N, Peto TJ, Zhang M, Liverani M, et al. Defining the
395 burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of
396 the Rural Febrile Illness project. *Wellcome Open Res.* 2022;6(64). doi:
397 10.12688/wellcomeopenres.16393.2.
- 398 13. Dittrich S, Tadesse BT, Moussy F, Chua A, Zorzet A, Tängden T, et al. Target Product Profile
399 for a Diagnostic Assay to Differentiate between Bacterial and Non-bacterial Infections and Reduce
400 Antimicrobial Overuse in Resource-Limited Settings: An Expert Consensus. *PLoS One.*
401 2016;11(8):e0161721. doi: 10.1371/journal.pone.0161721.
- 402 14. Jacobs L, Wong HR. Emerging infection and sepsis biomarkers: will they change current
403 therapies? *Expert Rev Anti Infect Ther.* 2016;14:929-41. doi: 10.1080/14787210.2016.1222272.
- 404 15. Chandna A, Aderie EM, Ahmad R, Arguni E, Ashley EA, Cope T, et al. Prediction of disease
405 severity in young children presenting with acute febrile illness in resource-limited settings: a
406 protocol for a prospective observational study. *BMJ Open.* 2021;11(1):e045826. doi:
407 10.1136/bmjopen-2020-045826.
- 408 16. Shrestha P, Dahal P, Ogbonnaa-Njoku C, Das D, Stepniewska K, Thomas NV, et al. Non-
409 malarial febrile illness: a systematic review of published aetiological studies and case reports from
410 Southern Asia and South-eastern Asia, 1980–2015. *BMC Med.* 2020;18:299. doi: 10.1186/s12916-
411 020-01745-0.
- 412 17. Schenz J, Weigand MA, Uhle F. Molecular and biomarker-based diagnostics in early sepsis:
413 current challenges and future perspectives. *Expert Rev Mol Diagn.* 2019;19(12):1069-78. doi:
414 10.1080/14737159.2020.1680285.

- 415 18. Hopkins H, Bassat Q, Chandler CI, Crump JA, Feasey NA, Ferrand RA, et al. Febrile Illness
416 Evaluation in a Broad Range of Endemicities (FIEBRE): protocol for a multisite prospective
417 observational study of the causes of fever in Africa and Asia. *BMJ Open*. 2020;10(7):e035632. doi:
418 10.1136/bmjopen-2019-035632.
- 419 19. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. *J Adv
420 Nurs*. 2000;32(4):1008-15.
- 421 20. Varndell W, Fry M, Lutze M, D E. Use of the Delphi method to generate guidance in
422 emergency nursing practice: A systematic review. *Int Emerg Nurs*. 2021;56:100867. doi:
423 10.1016/j.ienj.2020.100867.
- 424 21. Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM, et al. Defining
425 consensus: A systematic review recommends methodologic criteria for reporting of Delphi studies. *J
426 Clin Epidemiol*. 2014;67:401-9. doi: 10.1016/j.jclinepi.2013.12.002.
- 427 22. Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: How to decide its
428 appropriateness. *World J Methodol*. 2021;11(4):116-29. doi: 10.5662/wjm.v11.i4.116.
- 429 23. Yun GW, CW T. Comparative Response to a Survey Executed by Post, E-mail, & Web Form. *J
430 Compu-Mediated Com*. 2000;6(1):JCMC613. doi: 10.1111/j.1083-6101.2000.tb00112.x.
- 431 24. Boel A, Navarro-Compán V, Landewé R, van der Heijde D. Two different invitation
432 approaches for consecutive rounds of a Delphi survey led to comparable final outcome. *J Clin
433 Epidemiol*. 2021;129:31-9. doi: 10.1016/j.jclinepi.2020.09.034.
- 434 25. Holey EA, Feeley JL, Dixon J, Whittaker VJ. An exploration of the use of simple statistics to
435 measure consensus and stability in Delphi studies. *BMC Med Res Methodol*. 2007;7:52. doi:
436 10.1186/1471-2288-7-52.
- 437 26. Osborn J, Roberts T, Guillen E, Bernal O, Roddy P, Ongarello S, et al. Prioritising pathogens
438 for the management of severe febrile patients to improve clinical care in low- and middle-income
439 countries. *BMC Infect Dis*. 2020;20:117. doi: 10.1186/s12879-020-4834-1.

- 440 27. The Academy of Medical Sciences, National Academy of Science and Technology Philippines.
441 Improving the development and deployment of diagnostics in Southeast Asia: Workshop report.
442 London, UK: 2019.
- 443 28. Khambhati K, Bhattacharjee G, Singh V. Current progress in CRISPR-based diagnostic
444 platforms. *J Cell Biochem*. 2019;120(3):2721-5. doi: 10.1002/jcb.27690.
- 445 29. Kraemer S, Vaught JD, Bock C, Gold L, Katilius E, Keeney TR, et al. From SOMAmer-Based
446 Biomarker Discovery to Diagnostic and Clinical Applications: A SOMAmer-Based, Streamline
447 Multiplex Proteomic Assay. *PLoS One*. 2011;6(10):e26332. doi: 10.1371/journal.pone.0026332.
- 448 30. Médecins San Frontières, Foundation for Innovative New Diagnostics, World Health
449 Organization. Target product profile (TPP) for a semi-open multiplex multi-analyte diagnostic
450 platform. Geneva, Switzerland: World Health Organization; 2018.

452 **FIGURE LEGENDS**

453

454 **Figure 1.** The top seven analytes, in descending order of priority based on sum of weighted scores,
455 which should be considered for inclusion in multiplex lateral flow rapid diagnostic tests for
456 acute non-malarial fever using fingerprick blood as the test substrate, in the following
457 patient populations in Mainland Southeast Asia: (A) Children presenting to primary care
458 settings (B) Adults presenting to primary care settings (C) Children being admitted to
459 secondary care settings (D) Adults being admitted to secondary care settings. Children were
460 defined as patients aged >28 days and <15 years. An analyte in rank position 1 was weighted
461 seven times more than an analyte in rank position 7; the maximum sum of weighted scores
462 per analyte was 161.

463

464 **Figure 2.** The top seven analytes, in descending order of priority based on sum of weighted scores,
465 which should be considered for inclusion in multiplex lateral flow rapid diagnostic tests for
466 acute non-malarial fever using fingerprick blood as the test substrate, in the following
467 patient populations in Maritime Southeast Asia: (A) Children presenting to primary care
468 settings (B) Adults presenting to primary care settings (C) Children being admitted to
469 secondary care settings (D) Adults being admitted to secondary care settings. Children were
470 defined as patients aged >28 days and <15 years. An analyte in rank position 1 was weighted
471 seven times more than an analyte in rank position 7; the maximum sum of weighted scores
472 per analyte was 56.

473

474 **Figure 3.** The top seven analytes, in descending order of priority based on sum of weighted scores,
475 which should be considered for inclusion in multiplex lateral flow rapid diagnostic tests for





476 acute non-malarial fever using fingerprick blood as the test substrate, in the following
477 patient populations in South Asia: (A) Children presenting to primary care settings (B) Adults
478 presenting to primary care settings (C) Children being admitted to secondary care settings
479 (D) Adults being admitted to secondary care settings. Children were defined as patients aged
480 >28 days and <15 years. An analyte in rank position 1 was weighted seven times more than
481 an analyte in rank position 7; the maximum sum of weighted scores per analyte was 91.

482

483 **Figure 4.** The top five commonest aetiologies of acute fever, in descending order of perceived annual
484 incidence based on sum of weighted scores, in the following regions: (A) Mainland Southeast
485 Asia (B) Maritime Southeast Asia (C) South Asia. An analyte in rank position 1 was weighted
486 five times more than an analyte in rank position 5; the maximum sum of weighted scores per
487 aetiology was 115 for Mainland Southeast Asia, 40 for Maritime Southeast Asia, and 65 for
488 South Asia.





489

490 **Figure 5.** Reasons underlying the rankings made by individual expert participants of analytes which
491 should be prioritized for inclusion in multiplex lateral flow rapid diagnostic tests for acute
492 non-malarial fever using fingerprick blood as the test substrate, in the following patient
493 populations: (A) Children presenting to primary care settings (B) Adults presenting to
494 primary care settings (C) Children being admitted to secondary care settings (D) Adults being
495 admitted to secondary care settings. Children were defined as patients aged >28 days and
496 <15 years.







■ Rank position 1 ■ Rank position 2 ■ Rank position 3 ■ Rank position 4 ■ Rank position 5 ■ Rank position 6 ■ Rank position 7

Figure 1




■ Rank position 1 ■ Rank position 2 ■ Rank position 3 ■ Rank position 4 ■ Rank position 5 ■ Rank position 6 ■ Rank position 7

Figure 2





■ Rank position 1 ■ Rank position 2 ■ Rank position 3 ■ Rank position 4 ■ Rank position 5 ■ Rank position 6 ■ Rank position 7

Figure 3

A**Mainland Southeast Asia**

medRxiv preprint doi: <https://doi.org/10.1101/2022.07.25.22277986>; this version posted July 25, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

B**Maritime Southeast Asia****C****South Asia**

■ Rank position 1 ■ Rank position 2 ■ Rank position 3 ■ Rank position 4 ■ Rank position 5

Figure 4




Figure 5